Life SciencesPharmaceuticalsDrug Discovery

Celiac Disease (CD) - Epidemiology Forecast – 2030

Lowest Prices Guaranteed Length Publisher Published Date SKU
from $3,750 100 Pages DelveInsight August, 2020 DEL16307175
Lowest Prices Guaranteed
Price from $3,750
Length 100 Pages
Publisher DelveInsight
Published Date August, 2020
SKU DEL16307175

DelveInsight’s ‘Celiac Disease (CD) - Epidemiology Forecast – 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Celiac Disease (CD) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Celiac Disease (CD) Understanding
Celiac Disease (CD)—also known by coeliac disease, celiac sprue, non-tropical sprue, and gluten-sensitive enteropathy—is a chronic, immune-mediated enteropathy in which dietary gluten triggers an inflammatory reaction in the small intestine of genetically predisposed individuals. Gluten is a water-insoluble protein mass that remains when the wheat dough is washed to remove starch, albumins and other water-soluble proteins. Gluten and gluten-related proteins are present in wheat, rye and barley and are used widely in food processing to give the dough the desired baking properties, add flavors and improve texture. In celiac subjects, the ingestion of gluten leads to an enteropathy with an impairment of the mucosal surface and, consequently, abnormal absorption of nutrients. CD might be considered a syndrome, because of the wide spectrum of clinical manifestations and the involvement of various human systems.

CD shows atypical features in comparison to other autoimmune disorders, including the complete recovery of the mucosal damage as well as the reversibility of its progression and chronic dynamics, with total avoidance of gluten. Alternatively, it is now established that undiagnosed CD, might have severe consequences in children as well as in adult subjects.

CD is one of the better-characterized diseases related to the immune system with all the affected patients having the following:
• a genetic predisposition (either HLA-DQ2 or HLA-DQ8)
• a well-defined precipitating factor (gluten)
• highly sensitive and specific autoantibodies against the naturally occurring human enzyme, tissue transglutaminase (TG2)

According to the World Gastroenterology Organization, CD may be divided into two types: classical and non-classical. However, silent type CD also exits, which is also known as an asymptomatic CD. In case of silent type, patients do not complain of any symptoms, but still, experience villous atrophy damage to their small intestine. Studies have shown that even though patients thought they had no symptoms, after going on a strict gluten-free diet, they report better health and a reduction in acid reflux, abdominal bloating and distention and flatulence.

Celiac Disease (CD) Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of Celiac Disease (CD), Total Diagnosed Prevalent Population of Celiac Disease (CD), Gender-specific Diagnosed Prevalent Population of Celiac Disease (CD), Type-specific Diagnosed Prevalent Population of Celiac Disease (CD) and Age-specific Distribution of Celiac Disease (CD) in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Celiac Disease (CD) Detailed Epidemiology Segmentation
• The total prevalent population of Celiac Disease in the 7 major markets was found to be 6,334,993 in 2017.
• The total 7MM diagnosed prevalent cases of Celiac Disease in 2017 were 1,303,459 out of which the highest diagnosed prevalent cases of this disease were seen in the United States, which was 661,244.
• DelveInsight has found 238,048 and 423,196 cases of males and females in the United States, in 2017.
• It was found that in the United States the number of cases of Classical, Non-classical and Sub-clinical were 178,536, 343,847 and 138,861 respectively, in 2017.
• In the United States the maximum number of cases of Celiac Disease were found in the age group of 19–39 with 241,354 cases in 2017, while the lowest number of cases were found in the age group >80 with 13,224 cases in 2017.
• In the EU5 countries the total prevalent population of Celiac Disease was found to be maximum in Germany with 738,357 cases, followed by the United Kingdom with 650,676 cases in 2017. While, the least number of cases were found in Spain, i.e., 421,326 in 2017.
• In Japan, the prevalence of Celiac Disease was found to be 65,148 in 2017.

Scope of the Report
• The report covers the descriptive overview of Celiac Disease (CD), explaining its causes, signs and symptoms, pathophysiology.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of Celiac Disease (CD).
• The report provides the segmentation of the disease epidemiology for the 7MM by Total Prevalent Population of Celiac Disease (CD), Total Diagnosed Prevalent Population of Celiac Disease (CD), Gender-specific Prevalent Population of Celiac Disease (CD), Type-specific Prevalent Population of Celiac Disease (CD) and Age-specific Prevalent Population of Celiac Disease (CD).

Report Highlights
• Eleven Year Forecast of Celiac Disease (CD)
• 7MM Coverage
• Total Diagnosed Prevalent Population of Celiac Disease (CD)
• Through several secondary sources it is quite evident that the prevalence of Celiac Disease (CD) is higher among females than in males.
• DelveInsight has analyzed type-based data for Celiac Disease (CD). Celiac Disease (CD) can be of three types based on this data, namely, Classical, Non-classical and Sub-clinical Celiac Disease.
• The report also encompasses another major segment, i.e., Age-specific Prevalent Population of Celiac Disease (CD), wherein various age groups have been considered, such as 0–18, 19–39, 49–59, 60–79 and >80. It has been found that the prevalence of Celiac Disease (CD) is maximum in the 19–39 age group.
• Expected Launch of potential therapies, Larazotide Acetate (9 Meters Biopharma), Latiglutenase (ImmunogenX), PRV-015 (Provention Bio) and CNP-101/TAK-101 (Cour Pharmaceuticals/Takeda), may increase the market size in the coming years, assisted by an increase in diagnosed prevalent population of Celiac Disease (CD).

Key Questions Answered
• What is the disease risk, burden and unmet needs of Celiac Disease (CD)?
• What is the historical Celiac Disease (CD) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
• What would be the forecasted patient pool of Celiac Disease (CD) at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Celiac Disease (CD)?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Celiac Disease (CD) during the forecast period (2020–2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?

Reasons to buy
The Celiac Disease (CD) report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the 7MM Celiac Disease (CD) market.
• Quantify patient share distribution in the 7MM for Celiac Disease (CD).
• The Celiac Disease (CD) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The Celiac Disease (CD) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030


1 Key Insights
2 Celiac Disease Overview at a Glance
3 Executive Summary of Celiac Disease (CD)
4 Disease Background and Overview: Celiac Disease
4.1 Introduction
4.2 Types
4.2.1 Classical CD
4.2.2 Non-Classical CD
4.2.3 Silent CD
4.3 Causes
4.3.1 Genetics Factors
4.3.2 Environmental Factors
4.4 Symptoms
4.5 Pathogenesis
4.6 Pathophysiology
4.6.1 Genetics
4.6.2 Gluten, as an environmental trigger of CD
4.7 Clinical Presentation
4.8 Diagnosis
4.8.1 Diagnostic Tests of CD
4.9 Biomarkers for CD
4.9.1 Genetic Biomarkers in CD
4.9.2 Serological Biomarkers in CD
4.10 Differential diagnosis
5 Algorithm for Diagnosis of CD
6 Diagnostic Guidelines by the European Society for the Study of Coeliac Disease (ESsCD)
6.1 Recommendations on who should be tested for CD
6.2 Recommendations for Serology
6.3 Recommendations for Endoscopy and Histopathology
6.4 Recommendations for HLA-DQ2/8 Typing
6.5 Recommendations for other Diagnostic Tests
6.6 Recommendations for Diagnostic Confirmation
7 Diagnostic Guidelines by the World Gastroenterology Organization (WGO)
7.1 Recommendation for Diagnosis
7.2 Recommendations for Testing Patients
7.2.1 Patients with clinical manifestations suggestive of CD
7.2.2 Conditions associated with an increased risk for CD
7.2.3 First-degree relatives of patients with CD
7.3 Recommendations for Diagnostic Tests
7.3.1 Endoscopy in patients with suspected CD
7.3.2 Intestinal biopsy and histology
7.3.3 Serum antibody tests
8 Epidemiology and Patient Population: Key Findings
8.1 7MM Total Prevalent Population of Celiac Disease
8.2 MM Total Diagnosed Prevalent Population of Celiac Disease
9 Country Wise-Epidemiology of Celiac Disease
9.1 United States
9.1.1 Assumptions and Rationale
9.1.2 Total Prevalent Population of Celiac Disease in the United States
9.1.3 Total Diagnosed Prevalent Population of Celiac Disease in the United States
9.1.4 Gender-specific Diagnosed Prevalent Population of Celiac Disease in the United States
9.1.5 Type-specific Diagnosed Prevalent Population of Celiac Disease in the United States
9.1.6 Age-specific Distribution of Celiac Disease in the United States
9.2 EU5 Countries
9.2.1 Assumptions and Rationale
9.3 Germany
9.3.1 Assumptions and Rationale
9.3.2 Total Prevalent Population of Celiac Disease in Germany
9.3.3 Total Diagnosed Prevalent Population of Celiac Disease in Germany
9.3.4 Gender-specific Diagnosed Prevalent Population of Celiac Disease in Germany
9.3.5 Type-specific Diagnosed Prevalent Population of Celiac Disease in Germany
9.3.6 Age-specific Distribution of Celiac Disease in Germany
9.4 France
9.4.1 Assumptions and Rationale
9.4.2 Total Prevalent Population of Celiac Disease in France
9.4.3 Total Diagnosed Prevalent Population of Celiac Disease in France
9.4.4 Gender-specific Diagnosed Prevalent Population of Celiac Disease in France
9.4.5 Type-specific Diagnosed Prevalent Population of Celiac Disease in France
9.4.6 Age-specific Distribution of Celiac Disease in France
9.5 Italy
9.5.1 Assumptions and Rationale
9.5.2 Total Prevalent Population of Celiac Disease in Italy
9.5.3 Total Diagnosed Prevalent Population of Celiac Disease in Italy
9.5.4 Gender-specific Diagnosed Prevalent Population of Celiac Disease in Italy
9.5.5 Type-specific Diagnosed Prevalent Population of Celiac Disease in Italy
9.5.6 Age-specific Distribution of Celiac Disease in Italy
9.6 Spain
9.6.1 Assumptions and Rationale
9.6.2 Total Prevalent Population of Celiac Disease in Spain
9.6.3 Total Diagnosed Prevalent Population of Celiac Disease in Spain
9.6.4 Gender-specific Diagnosed Prevalent Population of Celiac Disease in Spain
9.6.5 Type-specific Diagnosed Prevalent Population of Celiac Disease in Spain
9.6.6 Age-specific Distribution of Celiac Disease in Spain
9.7 United Kingdom
9.7.1 Assumptions and Rationale
9.7.2 Total Prevalent Population of Celiac Disease in the United Kingdom
9.7.3 Total Diagnosed Prevalent Population of Celiac Disease in the United Kingdom
9.7.4 Gender-specific Diagnosed Prevalent Population of Celiac Disease in the United Kingdom
9.7.5 Type-specific Diagnosed Prevalent Population of Celiac Disease in the United Kingdom
9.7.6 Age-specific Distribution of Celiac Disease in the United Kingdom
9.8 Japan
9.8.1 Assumptions and Rationale
9.8.2 Total Prevalent Population of Celiac Disease in Japan
9.8.3 Total Diagnosed Prevalent Population of Celiac Disease in Japan
9.8.4 Gender-specific Diagnosed Prevalent Population of Celiac Disease in Japan
9.8.5 Type-specific Diagnosed Prevalent Population of Celiac Disease in Japan
9.8.6 Age-specific Distribution of Celiac Disease in Japan
10 Appendix
10.1 Bibliography
10.2 Report Methodology
11 DelveInsight Capabilities
12 Disclaimer
13 About DelveInsight
Table 1: Summary of Celiac Disease, Market, Epidemiology and Key Events (2017–2030)
Table 2: The symptoms of CD
Table 3: Marsh classification of histologic findings in CD
Table 4: Genetic Biomarkers in CD
Table 5: Serological Biomarkers in CD
Table 6: The main elements of the differential diagnosis of CD
Table 7: Total Prevalent Population of Celiac Disease in the 7MM (2017–2030)
Table 8: Total Diagnosed Prevalent Population of Celiac Disease in the 7MM (2017–2030)
Table 9: Total Prevalent Population of Celiac Disease in the United States (2017–2030)
Table 10: Total Diagnosed Prevalent Population of Celiac Disease in the United States (2017–2030)
Table 11: Gender-specific Diagnosed Prevalent Population of Celiac Disease in the United States (2017–2030)
Table 12: Type-specific Diagnosed Prevalent Population of Celiac Disease in the US (2017–2030)
Table 13: Age-specific Distribution of Celiac Disease in the United States (2017–2030)
Table 14: Total Prevalent Population of Celiac Disease in Germany (2017–2030)
Table 15: Total Diagnosed Prevalent Population of Celiac Disease in Germany (2017–2030)
Table 16: Gender-specific Diagnosed Prevalent Population of Celiac Disease in Germany (2017–2030)
Table 17: Type-specific Diagnosed Prevalent Population of Celiac Disease in Germany (2017–2030)
Table 18: Age-specific Distribution of Celiac Disease in Germany (2017–2030)
Table 19: Total Prevalent Population of Celiac Disease in France (2017–2030)
Table 20: Total Diagnosed Prevalent Population of Celiac Disease in France (2017–2030)
Table 21: Gender-specific Diagnosed Prevalent Population of Celiac Disease in France (2017–2030)
Table 22: Type-specific Diagnosed Prevalent Population of Celiac Disease in France (2017–2030)
Table 23: Age-specific Distribution of Celiac Disease in France (2017–2030)
Table 24: Total Prevalent Population of Celiac Disease in Italy (2017–2030)
Table 25: Total Diagnosed Prevalent Population of Celiac Disease in Italy (2017–2030)
Table 26: Gender-specific Diagnosed Prevalent Population of Celiac Disease in Italy (2017–2030)
Table 27: Type-specific Diagnosed Prevalent Population of Celiac Disease in Italy (2017–2030)
Table 28: Age-specific Distribution of Celiac Disease in Italy (2017–2030)
Table 29: Total Prevalent Population of Celiac Disease in Spain (2017–2030)
Table 30: Total Diagnosed Prevalent Population of Celiac Disease in Spain (2017–2030)
Table 31: Gender-specific Diagnosed Prevalent Population of Celiac Disease in Spain (2017–2030)
Table 32: Type-specific Diagnosed Prevalent Population of Celiac Disease in Spain (2017–2030)
Table 33: Age-specific Distribution of Celiac Disease in Spain (2017–2030)
Table 34: Total Prevalent Population of Celiac Disease in the United Kingdom (2017–2030)
Table 35: Total Diagnosed Prevalent Population of Celiac Disease in the United Kingdom (2017–2030)
Table 36: Gender-specific Diagnosed Prevalent Population of Celiac Disease in the United Kingdom (2017–2030)
Table 37: Type-specific Diagnosed Prevalent Population of Celiac Disease in the United Kingdom (2017–2030)
Table 38: Age-specific Distribution of Celiac Disease in the United Kingdom (2017–2030)
Table 39: Total Prevalent Population of Celiac Disease in Japan (2017–2030)
Table 40: Total Diagnosed Prevalent Population of Celiac Disease in Japan (2017–2030)
Table 41: Gender-specific Diagnosed Prevalent Population of Celiac Disease in Japan (2017–2030)
Table 42: Type-specific Diagnosed Prevalent Population of Celiac Disease in Japan (2017–2030)
Table 43: Age-specific Distribution of Celiac Disease in Japan (2017–2030)
Figure 1: Factors resulting in CD development
Figure 2: Pathogenesis of CD
Figure 3: Algorithm for Diagnosis of CD
Figure 4: Total Prevalent Population of Celiac Disease in the 7MM (2017–2030)
Figure 5: Total Diagnosed Prevalent Population of Celiac Disease in the 7MM (2017–2030)
Figure 6: Total Prevalent Population of Celiac Disease in the United States (2017–2030)
Figure 7: Total Diagnosed Prevalent Population of Celiac Disease in the United States (2017–2030)
Figure 8: Gender-specific Diagnosed Prevalent Population of CD in the United States (2017–2030)
Figure 9: Type-specific Diagnosed Prevalent Population of Celiac Disease in the United States (2017–2030)
Figure 10: Age-specific Distribution of Celiac Disease in the United States (2017–2030)
Figure 11: Total Prevalent Population of Celiac Disease in Germany (2017–2030)
Figure 12: Total Diagnosed Prevalent Population of Celiac Disease in Germany (2017–2030)
Figure 13: Gender-specific Diagnosed Prevalent Population of CD in Germany (2017–2030)
Figure 14: Type-specific Diagnosed Prevalent Population of Celiac Disease in Germany (2017–2030)
Figure 15: Age-specific Distribution of Celiac Disease in Germany (2017–2030)
Figure 16: Total Prevalent Population of Celiac Disease in France (2017–2030)
Figure 17: Total Diagnosed Prevalent Population of Celiac Disease in France (2017–2030)
Figure 18: Gender-specific Diagnosed Prevalent Population of CD in France (2017–2030)
Figure 19: Type-specific Diagnosed Prevalent Population of Celiac Disease in France (2017–2030)
Figure 20: Age-specific Distribution of Celiac Disease in France (2017–2030)
Figure 21: Total Prevalent Population of Celiac Disease in Italy (2017–2030)
Figure 22: Total Diagnosed Prevalent Population of Celiac Disease in Italy (2017–2030)
Figure 23: Gender-specific Diagnosed Prevalent Population of CD in Italy (2017–2030)
Figure 24: Type-specific Diagnosed Prevalent Population of Celiac Disease in Italy (2017–2030)
Figure 25: Age-specific Distribution of Celiac Disease in Italy (2017–2030)
Figure 26: Total Prevalent Population of Celiac Disease in Spain (2017–2030)
Figure 27: Total Diagnosed Prevalent Population of Celiac Disease in Spain (2017–2030)
Figure 28: Gender-specific Diagnosed Prevalent Population of CD in Spain (2017–2030)
Figure 29: Type-specific Diagnosed Prevalent Population of Celiac Disease in Spain (2017–2030)
Figure 30: Age-specific Distribution of Celiac Disease in Spain (2017–2030)
Figure 31: Total Prevalent Population of Celiac Disease in the United Kingdom (2017–2030)
Figure 32: Total Diagnosed Prevalent Population of Celiac Disease in the United Kingdom (2017–2030)
Figure 33: Gender-specific Diagnosed Prevalent Population of CD in the United Kingdom (2017–2030)
Figure 34: Type-specific Diagnosed Prevalent Population of Celiac Disease in the United Kingdom (2017–2030)
Figure 35: Age-specific Distribution of Celiac Disease in the United Kingdom (2017–2030)
Figure 36: Total Prevalent Population of Celiac Disease in Japan (2017–2030)
Figure 37: Total Diagnosed Prevalent Population of Celiac Disease in Japan (2017–2030)
Figure 38: Gender-specific Diagnosed Prevalent Population of Celiac Disease in Japan (2017–2030)
Figure 39: Type-specific Diagnosed Prevalent Population of Celiac Disease in Japan (2017–2030)
Figure 40: Age-specific Distribution of Celiac Disease in Japan (2017–2030)

$3,750
$11,250
 
Research assistance
US: 800.298.5699
Int'l: +1.240.747.3093
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks